Deciphera Pharmaceuticals
A clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $2.4b Valuation: $2.4b 14.7x EV/Revenue -11.5x EV/EBITDA | Acquisition | |
| Total Funding | 000k | ||
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (81 %) | 68 % | 128 % | 39 % | 22 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (37 %) | (74 %) | (769 %) | (628 %) | (312 %) | (136 %) | (128 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (38 %) | (74 %) | (769 %) | (633 %) | (312 %) | (133 %) | (119 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 29 % | 62 % | 630 % | 473 % | 267 % | 140 % | 143 % |
Source: Company filings or news article
Related Content
Deciphera Pharmaceuticals, a member of ONO Group, is a biopharmaceutical company dedicated to discovering, developing, and commercializing new medicines aimed at improving the lives of cancer patients. The company leverages its proprietary switch-control kinase inhibitor platform and extensive expertise in kinase biology to create a broad portfolio of targeted therapies. Deciphera primarily serves the oncology market, focusing on patients with various forms of cancer. The business model revolves around the research and development of novel drugs, followed by clinical trials and regulatory approvals, leading to commercialization. Revenue is generated through the sale of these approved medicines and potential partnerships or licensing agreements with other pharmaceutical companies.
Keywords: biopharmaceutical, cancer, kinase inhibitors, oncology, drug development, clinical trials, commercialization, kinase biology, proprietary platform, oncology market.
Investments by Deciphera Pharmaceuticals
Edit